β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖

doi:10.11904/j.issn.1002-3070.2024.04.007

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (4): 254-261.doi: 10.11904/j.issn.1002-3070.2024.04.007

β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖

高光强¹, 王发琳¹, 李娟², 田虹¹, 果思伽³, 于晓兰⁴, 杨婷婷¹, 刘家仁¹

1.哈尔滨医科大学附属第四医院检验科(哈尔滨 150001);
2.云南省阜外心血管病医院检验科;
3.深圳市妇幼保健医院检验科;
4.哈尔滨医科大学附属第六医院检验科

收稿日期:2023-12-13 修回日期:2024-08-08 出版日期:2024-08-28 发布日期:2024-09-25
通讯作者: 刘家仁,E-mail:jiarenliu@hrbmu.edu.cn
作者简介:高光强,男,(1970-),硕士,副主任技师,从事临床检验相关的工作。
基金资助:
国家自然科学基金(编号:82172580)

β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway

GAO Guangqiang¹, WANG Falin¹, LI Juan², TIAN Hong¹, GUO Sijia³, YU Xiaolan⁴, YANG Tingting¹, LIU Jiaren¹

1. Department of Clinical Laboratory,The 4th Affiliated Hospital of Harbin Medical University,Harbin 150001,China;
2. Department of Clinical Laboratory,Fuwai Yunnan Cardiovascular Hospital;
3. Department of Clinical Laboratory,Shenzhen Maternity and Child Health Hospital;
4. Department of Clinical Laboratory,The 6th Affiliated Hospital of Harbin Medical University

Received:2023-12-13 Revised:2024-08-08 Online:2024-08-28 Published:2024-09-25

摘要/Abstract

摘要： 目的探讨β-紫罗兰酮(β-Ionone,BI)通过调节核因子-κB(Nuclear factor kappa-B,NF-κB)对乳腺癌细胞增殖过程的抑制作用及其可能的机制。方法采用亚甲基蓝(Methylene blue,MB)法和MTT法测定人乳腺癌BT549细胞和MCF-7细胞活性,孔雀石绿磷酸盐法检测蛋白磷酸酶2A(Protein phosphatase 2A,PP2A)活性、免疫印迹法检测磷酸化P65(p-P65)(s536和s311)、PP2A(A、B和C)和磷酸化共济失调毛细血管扩张突变基因(Phosphorylation-ataxia telangiectasia-mutated gene,p-ATM)(s1981)蛋白水平。结果 BI可明显抑制人乳腺癌BT549细胞和MCF-7细胞的增殖,且呈时间和剂量依赖性,差异具有统计学意义(P＜0.01)。MCF-7细胞经BI处理后,NF-κB活性被显著抑制,表现为磷酸化P65(s536和s311)的蛋白水平显著降低,PP2A的蛋白水平升高,差异具有统计学意义(P＜0.05)。此外,BI还显著地降低PP2A抑制剂冈田酸(Okadaic acid,OA)对MCF-7细胞中P65蛋白和ATM蛋白的磷酸化作用。结论该研究表明BI通过抑制NF-κB活性来抑制乳腺癌细胞的增殖,其机制可能是BI通过增加PP2A活性调节NF-κB通路。

关键词: 乳腺癌, β-紫罗兰酮, 蛋白磷酸酶2A, 核因子-κB, 共济失调毛细血管扩张突变基因

Abstract: Objective This article aimed to explore the inhibitory effect of β-ionone(BI)on the proliferation of breast cancer cells through the nuclear factor kappa-B(NF-κB)pathway and its possible mechanism. Methods The methylene blue assay and MTT assay were used to determine the viability of breast cancer cells.The malachite green phosphate assay was used to detect the activity of protein phosphatase 2A(PP2A).Western blot was used to detect the levels of phosphorylated P65(s534 and s311)(p-P65),PP2A(A,B and C),and phosphorylated ataxia telangiectasia mutant(p-ATM)(s1981)protein. Results BI could significantly inhibit the proliferation of human breast cancer BT549 cells and MCF-7 cells in a time-and dose-dependent manner,and the difference was statistically significant(P＜0.01).After treated with BI,NF-κB activity was significantly inhibited in MCF-7 cells,as shown by a significant decrease in the level of phosphorylated P65(s311 and s534)protein and an increase in the level of PP2A protein,and the difference was statistically significant(P＜0.05).In addition,BI also significantly reduced the phosphorylation of P65 protein and ATM protein in MCF-7 cells by the PP2A inhibitor-okada acid(OA). Conclusion This study shows that BI inhibits the proliferation of breast cancer cells by inhibiting NF-κB activity,and its mechanism may be achieved by increasing PP2A activity to regulate the NF-κB pathway.

Key words: Breast cancer, β-Ionone, Protein phosphatase 2A, Nuclear factor kappa-B, Ataxia telangiectasia-mutated gene

中图分类号:

R736.1

高光强, 王发琳, 李娟, 田虹, 果思伽, 于晓兰, 杨婷婷, 刘家仁. β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖[J]. 实用肿瘤学杂志, 2024, 38(4): 254-261.

GAO Guangqiang, WANG Falin, LI Juan, TIAN Hong, GUO Sijia, YU Xiaolan, YANG Tingting, LIU Jiaren. β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway[J]. Journal of Practical Oncology, 2024, 38(4): 254-261.

参考文献

1 Liu JR,Dong HW,Chen BQ,et al.Fresh apples suppress mammary carcinogenesis and proliferative activity and induce apoptosis in mammary tumors of the Sprague-Dawley rat[J].J Agric Food Chem,2009,57(1):297-304.
2 Liu RH.Health-promoting components of fruits and vegetables in the diet[J].Adv Nutr,2013,4(3):384-392.
3 Kim KH,Ki MR,Min KH,et al.Advanced delivery system of polyphenols for effective cancer prevention and therapy[J].Antioxidants(Basel),2023,12(5):1048.
4 Zan L,Chen Q,Zhang L,et al.Epigallocatechin gallate(EGCG)suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25[J].Bioengineered,2019,10(1):374-382.
5 Xu X,Feng Y,Chen X,et al.Antitumor effects of seleno-beta-lactoglobulin on human breast cancer MCF-7 and MDA-MB-231 cells in vitro[J].Toxicol In Vitro,2019,61:104607.
6 Guven DC,Orhan C,Sahin K,et al.Data-driven identification of chemopreventive agents for breast cancer[J].Turk J Med Sci,2020,50(SI-2):1691-1696.
7 Dong HW,Wang K,Chang XX,et al.Beta-ionone-inhibited proliferation of breast cancer cells by inhibited COX-2 activity[J].Arch Toxicol,2019,93(10):2993-3003.
8 Dong HW,Zhang S,Sun WG,et al.Beta-ionone arrests cell cycle of gastric carcinoma cancer cells by a MAPK pathway[J].Arch Toxicol,2013,87(10):1797-1808.
9 Hou T,Wang Y,Dan W,et al.Beta-ionone represses renal cell carcinoma progression through activating LKB1/AMPK-triggered autophagy[J].J Biochem Mol Toxicol,2023,37(6):e23331.
10 Miranda MLP,Furtado KS,De Oliveira Andrade F,et al.Beta-ionone inhibits nonalcoholic fatty liver disease and its association with hepatocarcinogenesis in male Wistar rats[J].Chem Biol Interact,2019,308:377-384.
11 Vieira A,Heidor R,Cardozo MT,et al.Efficacy of geraniol but not of beta-ionone or their combination for the chemoprevention of rat colon carcinogenesis[J].Braz J Med Biol Res,2011,44(6):538-545.
12 Liu Q,Dong HW,Sun WG,et al.Apoptosis initiation of beta-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway[J].Arch Toxicol,2013,87(3):481-490.
13 Liu JR,Yang BF,Chen BQ,et al.Inhibition of beta-ionone on SGC-7901 cell proliferation and upregulation of metalloproteinases-1 and-2 expression[J].World J Gastroenterol,2004,10(2):167-171.
14 Tan AC,Konczak I,Sze DM,et al.Molecular pathways for cancer chemoprevention by dietary phytochemicals[J].Nutr Cancer,2011,63(4):495-505.
15 Liu W,Zhou J,Geng G,et al.Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-kappaB[J].Invest New Drugs,2014,32(2):227-234.
16 Poma P.NF-kappaB and disease[J].Int J Mol Sci,2020,21(23):9181.
17 Mirzaei S,Saghari S,Bassiri F,et al.NF-kappaB as a regulator of cancer metastasis and therapy response:a focus on epithelial-mesenchymal transition[J].J Cell Physiol,2022,237(7):2770-2795.
18 Kunnumakkara AB,Shabnam B,Girisa S,et al.Inflammation,NF-kappaB,and chronic diseases:How are they linked?[J].Crit Rev Immunol,2020,40(1):1-39.
19 Ezzati M,Yousefi B,Velaei K,et al.A review on anti-cancer properties of quercetin in breast cancer[J].Life Sci,2020,248:117463.
20 Sun WG,Song RP,Wang Y,et al.Gamma-tocotrienol-inhibited cell proliferation of human gastric cancer by regulation of nuclear factor-kappaB activity[J].J Agric Food Chem,2019,67(1):441-451.
21 Khan H,Ullah H,Castilho P,et al.Targeting NF-kappaB signaling pathway in cancer by dietary polyphenols[J].Crit Rev Food Sci Nutr,2020,60(16):2790-2800.
22 Liu JR,Liu Q,Khoury J,et al.Hypoxic preconditioning decreases nuclear factor kappaB activity via Disrupted in Schizophrenia-1[J].Int J Biochem Cell Biol,2016,70:140-148.
23 Remmerie M,Janssens V.PP2A:A promising biomarker and therapeutic target in endometrial cancer[J].Front Oncol,2019,9:462.
24 Seo S H,Kim SG,Shin JH,et al.Toxoplasma GRA16 inhibits NF-kappaB activation through PP2A-B55 upregulation in non-small-cell lung carcinoma Cells[J].Int J Mol Sci,2020,21(18):6642.
25 Shouse GP,Nobumori Y,Panowicz MJ,et al.ATM-mediated phosphorylation activates the tumor-suppressive function of B56gamma-PP2A[J].Oncogene,2011,30(35):3755-3765.
26 Dunphy G,Flannery SM,Almine JF,et al.Non-canonical activation of the DNA sensing adaptor STING by ATM and IFI16 mediates NF-kappaB signaling after nuclear DNA damage[J].Mol Cell,2018,71(5):745-760.

[1]	李倩妮, 徐灵燕, 李健, 姚雪佩, 刘美娜. 乳腺癌多维治疗质量纵向评价的趋势分析[J]. 实用肿瘤学杂志, 2024, 38(4): 213-220.
[2]	邵禹铭, 朱坤兵, 张洁. SP/NK-1R系统在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(4): 268-272.
[3]	殷海燕, 淳志明, 马巧君, 成涵, 丁高恒, 张海燕, 刘玉琴. 2019年甘肃省肿瘤登记地区女性乳腺癌流行特征及2010-2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(3): 141-148.
[4]	黑龙江省医学会乳腺肿瘤学组. 黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)[J]. 实用肿瘤学杂志, 2024, 38(2): 71-78.
[5]	孟凡岗, 陈飞, 甄立军. DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 88-95.
[6]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.
[7]	谢俊岭. 活化白细胞黏附分子在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 45-49.
[8]	冯楚然, 曹剑钊, 陈子印, 张大昕, 鲁海玲. 乳腺癌放射性心脏损伤及其预防措施的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 513-518.
[9]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[10]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[11]	王新萍, 张自云, 王学东. 非编码RNA在乳腺癌化疗耐药中作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 454-458.
[12]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[13]	陈飞, 王颖, 曾传琴. B7-H4在乳腺癌组织中的表达及其与患者新辅助化疗后腋窝淋巴结转移的相关性分析[J]. 实用肿瘤学杂志, 2023, 37(4): 360-366.
[14]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[15]	马艳玲, 钱立庭, 魏东华, 尹惠萍, 张娟, 张小鹏. 2014—2017年安徽省合肥市城市乳腺癌高危人群筛查率及其影响因素分析[J]. 实用肿瘤学杂志, 2023, 37(3): 200-206.

β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖

β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价